Theravance Biopharma(TBPH) - 2023 Q1 - Earnings Call Presentation

Progress Against 2023 Financial Targets Substantial Progress Made on Buyback Program ‣ Expanded Capital Return Program to $325M, and expect to complete by end of 2023 Co-promotion agreement with VIATRISTM (35$43.7 $49.1$53.4 $55.7$47.0 0 10 20 30 40 50 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Total YUPELRI Net Sales ($M) 1. In the US, Viatris is leading the commercialization of YUPELRI, and Theravance Biopharma co-promotes the product under a profit and loss sharing arrangement (65% to Viatr ...